glp-1 next generation Revolutionizing obesity treatment: The emerging role of receptor agonists and next-generation pharmacotherapies How are GLP-1 drugs reshaping

2014;348:g2366

21,23 Managing other preexisting GI conditions, such as gastroesophageal reflux disease or constipation, before initiating GLP-1 RAs can reduce the likelihood of severe GI AEs and improve overall tolerability

This perspective contrasts with failed targets , for which rigorous clinical evaluation has demonstrated unacceptable on-target toxicity or lack of efficacy at therapeutically relevant exposures

What is most disturbing is the rise in children under the age of 5 who are now overweight or living with obesity

Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden

Challenges and management of liver cirrhosis: Practical issues in the therapy of patients with cirrhosis due to NAFLD and NASH